基于PEERs的国内他汀类药物经济学研究质量评估  

Quality Assessment of Domestic Statin Economics Research Based on the Guidelines for Quality Assessment of Pharmacoeconomic Evaluation Report(PEERs)

作　　者：沈瑛莹 何晓静[1] 菅凌燕[1] SHEN Yingying;HE Xiaojing;JIAN Lingyan(Department of Pharmacy,Shengjing Hospital of China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院药学部,沈阳110004

出　　处：《医药导报》2021年第11期1604-1608,共5页Herald of Medicine

基　　金：20132014国家临床药学重点专科项目。

摘　　要：目的了解国内他汀类药物经济学研究质量,明确其中需要改善和规范的关键点。方法利用《药物经济学评价报告质量评估指南》(简称“PEERs”)对中国学者已公开发表的他汀类药物经济学文献进行质量评估。结果共纳入他汀类药物经济学研究文献66篇,PEERs符合率27.3%,所有文献需在“结果的外推性、局限性和不确定性”“药物经济学评价方法及研究设计类型的相关阐述”“数据的完整性及其处理方法”等方面进一步完善。结论国内他汀类药物经济学研究总体质量仍待提升,推荐我国学者在撰写药物经济学评价报告时参照PEERs指南中的评价要素,更全面、严谨地阐述报告内容。Objective To investigate the quality of domestic economic evaluations of statins and to point out the key points for further improvement and standardization in this field.Methods The Guidelines for Quality Assessment of Pharmacoeconomic Evaluation Report(PEERs)was used to analyze the published literatures of economic evaluation of statins in China.Results Sixty-six research literatures on pharmacoeconomic evaluations of statins were included,with a compliance rate of 27.3%according to PEERs.All literatures needed to be further improved in aspects of"extrapolation,limitation and uncertainty of results","elaboration on pharmacoeconomic evaluation methods and research design types","data integrity and processing methods"and so on.Conclusion The quality of domestic pharmacoeconomic research of statins still needs to be improved.It is recommended that Chinese scholars should refer to the evaluation elements in the PEERs guidelines to elaborate the contents of the report more comprehensively and rigorously.

关 键 词：他汀类药物 药物经济学 质量评估 

分 类 号：R972.6[医药卫生—药品] R969[医药卫生—药学]